Immuneering Corporation (IMRX), a late-stage clinical oncology company, is expected to present updated data from its Phase 2a trial of Atebimetinib in combination with modified gemcitabine/nab-paclitaxel in treating pancreatic cancer at the annual meeting of the American Society of Clinical Oncology (ASCO) on June 1, 2026.
Atebimetinib (IMM-I-104) is a once-daily, oral, investigational Deep Cyclic inhibitor of MEK that provides more durable anti-tumor activity to improve survival across different indications, including pancreatic cancer.
The Phase 2a trial evaluates atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) to treat patients with advanced or metastatic pancreatic cancer as a first-line treatment. The presentation will include survival data across 55 first-line patients, comprising the initial cohort of 34 patients and an additional 21 patients.
The company is advancing atebimetinib, and expects to initiate a Phase 3 trial in combination with chemotherapy for treating pancreatic cancer, dubbed MAPKeeper trial by mid-2026.
IMRX closed Tuesday at $5.55, up 0.36%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.